Skip to content

Nexstim Plc announces the change of CEO

Nexstim Plc (NXTMH:HEX, NXTMS:STO), a medical technology company aiming to improve rehabilitation for stroke patients with the use of non-invasive brain stimulation, announces that Janne Huhtala has stepped down as CEO of Nexstim to explore new opportunities. Martin Jamieson, Nexstim’s Chairman, will assume the position of CEO whilst a search for a substantive CEO has been initiated.

Commenting on the news, Janne Huhtala said: “I leave Nexstim after working more than eight years with the team and after seeing the technology platform developed towards commercialisation and I am a firm believer that this Company will make a significant impact on patients’ lives in the future.”

Commenting on the release, the CEO, Martin Jamieson, said: “We thank Janne for his contribution to Nexstim particularly in the development phase and through the IPO. We wish him well for the future and look forward to appointing a new CEO. The company has tremendous potential and the new CEO will drive the transition from clinical development to commercialisation particularly in the US domestic market.”

Martin Jamieson, CEO

For further information please visit or contact:

Martin Jamieson, Chief Executive Officer

UB Securities Ltd (Certified Adviser)
+358 (0)9 2538 0246

Consilium Strategic Communications
Mary-Jane Elliott / Ivar Milligan / Laura

+44 (0)20 3709 5700

About Nexstim Plc
Nexstim is a medical technology company aiming to improve rehabilitation for stroke patients. Nexstim has pioneered its technology in brain diagnostics with the Navigated Brain Stimulation (NBS) system as the first and only FDA-cleared and CE-marked navigated Transcranial Magnetic Stimulation (nTMS) device for pre-surgical mapping of the motor and speech cortices. Based on the same technology platform, the company has developed a device for stroke therapy called Navigated Brain Therapy (NBT®). Nexstim’s shares are listed on Nasdaq First North Finland and Nasdaq First North Sweden. For more information please visit


Source: Nexstim